News & Videos - TISSUE REGENIX GRP. ORD 0.1P - English

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative 05-Apr-2023 / 14:55 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative...

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Operating leverage 27-Sep-2022 / 07:15 GMT/BST Hardman & Co Research on Tissue Regenix (TRX): Operating leverage Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics and dental markets. 1H’22 results provided...

Hardman & Co Research Hardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct 11-Aug-2022 / 16:30 GMT/BST Hardman & Co Video | Analyst interview Tissue Regenix Group plc: Significantly undervalued which should correct Tissue Regenix Group plc (TRX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews. Martin reminds us of what the company does, summrises the key details from its trading update, talks though the implications...

Hardman & Co Research Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential 19-Jul-2022 / 14:30 GMT/BST Hardman & Co Research | Tissue Regenix (TRX) Strong 1H’22 sales suggest upside potential Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery,...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability 19-Apr-2022 / 07:15 GMT/BST Hardman & Co Research on Tissue Regenix (TRX): On pathway to sustainability Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets....

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery 19-Oct-2021 / 13:15 GMT/BST Hardman & Co Research: Faster-than-anticipated recovery Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. Interim results...

Hardman & Co Research Hardman & Co Research: Q&A with Dr Martin Hall on Tissue Regenix Group Plc: New capacity now on stream 14-Jul-2021 / 15:15 GMT/BST Hardman & Co Video | Q&A with Martin Hall on Tissue Regenix Group Plc | New capacity now on stream Tissue Regenix (TRX) is the topic of conversation when Martin Hall joined DirectorsTalk. Martin gives us a reminder of what Tissue Regenix does, discusses the poor operating performance, share prices, key messages from the report and thoughts on...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Poised for growth 30-Jun-2021 / 11:55 GMT/BST Hardman & Co Research: Poised for growth TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. In the past two years, the focus has been on its commercial...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability 07-Oct-2020 / 13:50 GMT/BST Hardman & Co Research: Funded through to profitability TRX is focused on the development and commercialisation of two proprietary decellularisation technologies for repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of approved regenerative medicine products for the biosurgery, orthopaedics and dental markets. Over the past two years, TRX has...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Restructured to satisfy product demand 06-Feb-2020 / 07:15 GMT/BST Hardman & Co Res earch : Restructured to satisfy product demand Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue ( dCELL ) and bone ( BioRinse ). Following the acquisition of CellRight in...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Credit facilities expand cash runway to 2021 20-Jun-2019 / 14:22 GMT/BST Hardman & Co Research: Credit facilities expand cash runway to 2021 Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the acquisition of...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Expanded GPO coverage secured 10-Apr-2019 / 07:20 GMT/BST Hardman & Co Research: Expanded GPO coverage secured Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). Following its acquisition of CellRight, management embarked on...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): 2018 in review: foundations laid for osteobiologics 17-Dec-2018 / 11:56 GMT/BST Hardman & Co: 2018 in review: foundations laid for osteobiologics TRX has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for the repair of soft tissue (dCELL) and bone (BioRinse). With organic growth being boosted by the...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Strategy delivering growth above expectations 14-Sep-2018 / 07:15 GMT/BST Hardman & Co: Strategy delivering growth above expectations TRX has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. The company has two proprietary decellularisation technology platforms, for the repair of tissues and bone. 2017 was a dynamic year for the group, growth being boosted by the...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): 1H'18 preview: organic plus inorganic growth 02-Aug-2018 / 10:10 GMT/BST Hardman & Co: 2018: 1H'18 preview: organic plus inorganic growth TRX has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. The company has two proprietary decellularised technology platforms for the repair of tissues and bone. 2017 was a dynamic year for the group, growth being boosted by the...

Hardman & Co Hardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note 05-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: CellRight hits the right note CellRight hits the right note - Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. The company has two proprietary decellularised technology platforms for the repair of tissues and bone. 2017 was a dynamic year for the group, growth being...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

...